Flash
›
Racura Oncology Ltd (RAC.AX) Deep Dive Video
Racura Oncology Ltd (RAC.AX) Deep Dive Video
Summary
A reformulated “lost” AML drug resurfaces as a potential MYC-silencing G4 platform—huge upside if RC220 bridges cleanly, but execution and trial binary risk remain decisive.
View RAC.AX stock page
·
Read the RAC.AX research report
Loading the video player…